| 000 | 01864 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515164131.0 | ||
| 264 | 0 | _c20090821 | |
| 008 | 200908s 0 0 eng d | ||
| 022 | _a1464-3405 | ||
| 024 | 7 |
_a10.1016/j.bmcl.2009.03.005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDebenham, John S | |
| 245 | 0 | 0 |
_aPyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cMay 2009 |
||
| 300 |
_a2591-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCannabinoid Receptor Agonists |
| 650 | 0 | 4 |
_aCannabinoids _xchemistry |
| 650 | 0 | 4 |
_aChemistry, Pharmaceutical _xmethods |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 |
_aObesity _xdrug therapy |
| 650 | 0 | 4 | _aProtein Structure, Tertiary |
| 650 | 0 | 4 |
_aPyrimidines _xchemistry |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aReceptor, Cannabinoid, CB1 _xagonists |
| 650 | 0 | 4 |
_aReceptor, Cannabinoid, CB2 _xagonists |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aMadsen-Duggan, Christina B | |
| 700 | 1 | _aWang, Junying | |
| 700 | 1 | _aTong, Xinchun | |
| 700 | 1 | _aLao, Julie | |
| 700 | 1 | _aFong, Tung M | |
| 700 | 1 | _aSchaeffer, Marie-Therese | |
| 700 | 1 | _aXiao, Jing Chen | |
| 700 | 1 | _aHuang, Cathy C R-R | |
| 700 | 1 | _aShen, Chun-Pyn | |
| 700 | 1 | _aSloan Stribling, D | |
| 700 | 1 | _aShearman, Lauren P | |
| 700 | 1 | _aStrack, Alison M | |
| 700 | 1 | _aEuan Macintyre, D | |
| 700 | 1 | _aHale, Jeffrey J | |
| 700 | 1 | _aWalsh, Thomas F | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 19 _gno. 9 _gp. 2591-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2009.03.005 _zAvailable from publisher's website |
| 999 |
_c18765300 _d18765300 |
||